Position in UTHR
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$28,711,029
+$12,520,897 QoQ
Shares Held
52,989
+94.1% QoQ
Ownership
0.124%
of shares outstanding
% of Portfolio
10.84%
of 13F equity value
Holder Rank
#105
of 870 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in UTHR Over Time
Shares Held
Position Value (USD)
Derivatives in UTHR
reported options exposure · as of Mar 31, 2026CallValue
$23,837,796
CallShares
40,200
PutValue
$11,859,600
PutShares
20,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026DIADEMA PARTNERS LP holds $36,596,582 across 6 Drug Manufacturers - Specialty & Generic names. UTHR ranks #1 (78.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UTHR |
UNITED THERAPEUTICS Corp
This page
|
52,989 | $28,711,029 | |
| 2 | BIOA |
BioAge Labs, Inc.
|
146,334 | $3,586,646 | |
| 3 | INDV |
Indivior Pharmaceuticals, Inc.
|
67,512 | $2,770,017 | |
| 4 | XERS |
Xeris Biopharma Holdings, Inc.
|
132,746 | $1,051,348 | |
| 5 | AYTU |
Aytu Biopharma, Inc
|
148,546 | $319,373 | |
| 6 | TLPH |
Talphera, Inc.
|
153,563 | $158,169 |
All Filings in UTHR
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $28,711,029 | 52,989 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $23,837,796 | 40,200 | Call | Sole | 2026-05-15 | |
| 2026-03-31 | $16,190,132 | 27,303 | Shares | Sole | 2026-05-15 | |
| 2026-03-31 | $11,859,600 | 20,000 | Put | Sole | 2026-05-15 | |
| 2025-12-31 | $4,872,500 | 10,000 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||